Navigation Links
Dow AgroSciences, World Wide Wheat Agree to Collaborate on Wheat

INDIANAPOLIS and PHOENIX, June 2 /PRNewswire/ -- Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company (NYSE: DOW), and World Wide Wheat (W3) LLC of Phoenix, Arizona, announced today a collaboration agreement for the development and commercialization of advanced germplasm and traits in wheat.

The concept of the collaboration is to couple Dow AgroSciences' expertise in seeds and traits with W3's proprietary wheat germplasm and robust breeding capabilities. Dow AgroSciences' experience in seed and trait commercialization will be leveraged to bring the next generation of wheat to market. W3 brings more than 40 years of plant breeding to the collaboration and will be able to leverage Dow AgroSciences' reach in key global markets such as North America, Latin America, Europe and Australia.

"We are very pleased to be working with W3, an industry leader in wheat breeding, to launch a portfolio of new products in the near future," said Jerome Peribere, president and CEO of Dow AgroSciences. "This collaboration will build upon our current seed portfolio by expanding into wheat -- a very important global crop which supplies a significant amount of the daily nutrition in human diets. And, we look forward to utilizing our R&D breeding and trait technologies such as EXZACT(TM) Precision Technology to bring advancements in productivity and quality to market."

"We are excited to collaborate with Dow AgroSciences, a significant player in seeds and traits," said Sheldon Richardson, chairman and CEO of W3. "With Dow AgroSciences as our partner, we can leverage customer relationships within the food chain and their marketing and commercialization expertise. Our four decades of plant breeding experience brings a wide diversity of germplasm offering of high yielding varieties developed for markets around the world."

About World Wide Wheat (W3)

World Wide Wheat (W3), headquartered in Phoenix, is one of the world's leading independent plant breeding companies whose research is devoted to the improvement of wheat, barley and oats - major food crops of the world. World Wide Wheat operates research stations in 18 countries, producing superior varieties of cereal grains that are not genetically modified. For more information see

About Dow AgroSciences

Dow AgroSciences LLC, based in Indianapolis, Indiana, USA, is a top-tier agricultural company that combines the power of science and technology with the "Human Element" to constantly improve what is essential to human progress. Dow AgroSciences provides innovative technologies for crop protection, pest and vegetation management, seeds, traits, and agricultural biotechnology to serve the world's growing population. Global sales for Dow AgroSciences, a wholly owned subsidiary of The Dow Chemical Company, are $4.5 billion. Learn more at

SOURCE Dow AgroSciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Georgia Reproductive Specialists Participates in Largest-Ever In Vitro Fertilization Clinical Trial in the World
2. Aspirin Named 8th World Wonder by Majority of Americans
3. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
4. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
5. A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug Phenoxodiol
6. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
7. Genasense(R) Data in Melanoma to be Presented in Opening Session at First Worldwide Melanoma Center Meeting of the European Association of Dermato-Oncology
8. WorldHeart Announces Further Milestone in Miniaturized Assist Pump Development
9. Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
10. Pivotal Ustekinumab (CNTO 1275) Phase 3 Data to Debut at World Congress of Dermatology Meeting
11. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
Post Your Comments:
(Date:11/30/2015)... Wash. , Nov. 30, 2015  Precision ... Post-Processing services, is pleased to announce a dramatic ... medical imaging services. Building on its ISO-9001:2008 certification ... and implemented comprehensive Core Lab protocols and procedures. ... variety of research activities.  Their Core Lab services ...
(Date:11/30/2015)... , November 30, 2015 PFE ... at up to 10 G protein-coupled receptor (GPCR) targets ... to research and develop potential new medicines directed at ... multiple therapeutic areas. --> Heptares Therapeutics ("Heptares"), ... and wholly-owned subsidiary of Sosei Group Corporation ("Sosei"; TSE ...
(Date:11/30/2015)... , November 30, 2015 Mexico Healthcare ... and Life Sciences Report 2015 . --> Pharmaboardroom releases ... . Latin America , a country of ... , a country of over 122 million people. --> ... healthcare, pharmaceuticals, or life sciences insights into the second largest pharma ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... Sikka Software announced today ... Meeting. Their Ecosystem empowers dentists to make complex business decisions by providing the tools ... receive a free fee survey with 10 procedures customized by zip code. , ...
(Date:11/30/2015)... Grove, IL (PRWEB) , ... November 30, 2015 , ... ... for an emerging pharmaceutical company. Because it is so important to this key industry ... “Success Factors in your IND Filing” on December 4th at 11am EST. , Federal ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... has verified that their Vasont Universal Integrator (VUI) extension unites with Syncro Soft’s ... and managing content as a continuous process with the latest release of oXygen® ...
(Date:11/30/2015)... California (PRWEB) , ... November 30, 2015 , ... ... a strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue ... synthetic polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support ...
(Date:11/30/2015)... ... 2015 , ... Healthjump, Inc. announced that it has acquired ... development and support company. The purchase will expand the capability to serve clients ... the services currently provided by Healthjump. , Through this purchase, ...
Breaking Medicine News(10 mins):